AACC American Association for Clinical Chemistry
Avatar

Evaluation of Sex-Specific 99th Percentile URLs for hs-cTn Assays: Will the Use of 99th Percentile URLs Influence the Detection Rates of Myocardial Injury and Infarction? What Are the Sex-Specific 99th Percentiles Variations?

By AACC American Association for Clinical Chemistry FEATURING Fred S. Apple
October 7, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

32:12
Merck Cardiology

A Treatment Option for Heart Failure Patients With Reduced Ejection Fracti…

Feat. B. Hilkert, B. Colucci

Featured Video

14:46
Boston Scientific

Predicting Heart Failure Events in Patients with Implanted Devices: How Su…

Feat. J. Boehmer

Related Content

AUTOPLAY
World Stroke Organization

Evidence Based Stroke Medicine Webinar

Wed, Jan 26, 2022
06:38
Allan Jaffe

What Does Elevated Troponin Mean in COVID-19?

25:21
Congenital and Structural Interventions

LAA Closure for Atrial Fibrillation using Occlusion Device

Feat. H. Sievert
13:01
Innovations in Cardiac Rhythm Management

Watchman Implantation: Tips and Tricks

Feat. S. Doshi
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - How to…

47:43
Medtronic

My Patient's Short-Term Cardiac Monitor Delivered - How to Transition …

12:23
American Heart & Vascular Institute

SGLT2 Inhibitors for HF: Is this Therapy Helpful for Reducing the Hospital…

Feat. M. Tipton
29:57
Scripps Health

Hypertrophic Cardiomyopathy: MRI to Mavacamten

Feat. J. Gonzalez
14:44
26th Annual San Diego Heart Failure Symposium

Broadening Indications for the Use of Angiotensin Receptor Neprilysin Inhi…

Feat. C. Yancy
19:47
Complex Coronary Cases

Therapy Post PCI: What Is the Rationale for DAPT and OAC? When to Use Trip…

Feat. U. Baber
17:35
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhib…

Feat. B. Greenberg
64:40
Cardiac Contractility Modulation

CCM® Therapy - Mechanism of Action, Patient Selection and Identification

Feat. A. Kaplan, H. Saltzman
63:10
Cardiac Contractility Modulation

Failure Is not an Option! Implementing CCM into your Practice

Feat. F. Syed, M. Goldschmidt, I. Rao
88:01
Cardiac Contractility Modulation

The Comparison and Advantages of the Use of Device Therapy in Heart Failur…

Feat. V. Thohan, G. Tomassoni, R. Doshi, F. Abi-Samra, I. Rao
21:28
Keck School of Medicine of USC

Takotsubo Syndrome: What Diagnostic Criteria Are Available? Which Drugs to…

Feat. H. Van Herle
24:58
Boston Scientific

How to Manage HF using a Remote Heart Failure Diagnostic and Monitoring So…

Feat. J. Boehmer
27:33
Boston Scientific

Multi-Sensor Heart Failure Monitoring: What Are the Benefits of HeartLogic…

Feat. J. Boehmer
05:10
Boston Scientific

HeartLogic™: The First FDA-Approved Predictive Analytic Alert in an Implan…

Feat. A. Hernandez, J. Boehmer, J. Singh, C. Fier, N. Albert
16:54
Cardiac Contractility Modulation

Cardiac Contractility Modulation: How it Works

Feat. J. Ehrlich, H. Levin
33:38
Cardiac Contractility Modulation

AAHFN Advanced 2020 - CCM® in HF - Mechanism and Clinical Evidence

Feat. R. Kahwash, N. Albert
61:12
Cardiac Contractility Modulation

Assessing Heart Failure Patients - Where Does CCM® Therapy Fit

Feat. S. Brune, N. Bonnet, M. Arnold